Диссертация (1140095), страница 13
Текст из файла (страница 13)
A Systematic Review and Metaanalysis./ JacquesRizkallah, S. F. Paul Man, Don D. Sin.// CHEST.- 2009.-Vol. 135.-P. 786–793.104.Rodeghiero, F. Activated protein C resistance and factor V Leidenmutation are independent risk factors for venous thromboembolism. / F Rodeghiero,A.Tosetto // Ann Intern Med.- 1999.- Vol. 130(8).- P. 643-50.105.Roest, M. Plasminogen Activator Inhibitor 4G polymorphism isassociated with decreased risk of cerebrovascular Mortality in Older Women. /M.Roest, Y.T. van der Schouw, J.D. Banga [et al.]// Circulation.- 2000. –Vol. 101.P. 67-72.106.Rosendaal, F.R.
Risk factors for venous thrombotic disease. /F.R.Rosendaal// Haemost.- 1999.- Vol. 82. P. 610–619.107.Rosendaal, FR. Venous thrombosis: the role of genes, environment,and behavior". /F.R. Rosendaal// Hematology Am. Soc. Hematol. Educ. Program.2005.- Vol. (1).- P. 1–12.108.Rucinski, B., [et al.], Blood, 53, 47 (1979).109.S P, Levine. Increased Plasma Concentrations of Platelet Factor 4 inCoronary Artery Disease. /S P Levine, J Lindenfeld, J B Ellis [et al.]// Circulation.1981.- Vol. 64.- P. 626-632.110.Salomon, O.
Single and combined prothrombotic factors in patientswith idiopathic venous thromboembolism: prevalence and risk assessment./94O.Salomon, D.M.Steinberg, A.Zivelin [et al.]// Arterioscler Thromb Vasc Biol.1999.- Vol. 19.- P. 511–518.111.Schafer, A. Hypercoagulable states: molecular genetics to clinicalpractice.
/ A. Schafer// Lancet.- 1994.- Vol. 344.- P. 1739–1742.112.Schafer, K. Disruption of the plasminogen activator inhibitor-1 genereduces the adiposity and improves the metabolic profile of genetically obese anddiabetic ob/ob mice. / K Schafer, K Fujisawa, S Konstantinides, DJ Loskutoff. //FASEB J.- 2001.- Vol.
15(8).-P. 1840–2.113.Schleef, R.R. Bleeding diathesis due to decreased functional activityof type 1 plasminogen activator inhibitor. / R.R.Schleef, D.L.Higgins, E.Pillemer,L.J. Levitt// Clin. Invest.- 1989.-Vol. 83.- P. 1747-1752.114.Schneiderman, J. Increased type-1 plasminogen activator inhibitorgene expression in atherosclerotic human arteries. / J Schneiderman, MS Sawdey,MR Keeton [et al.] // Proc Natl Acad Sci U S A.- 1992.- Vol.
89(15). - P. 6998–7002.115.Silva, DR. D-dimer levels in stable COPD patients: a case-controlstudy. / DR Silva, AC Coelho, MB Gazzana [et al.] // COPD.- 2012.- Vol. 9(4).- P.426-31.116.The Global initiative for chronic Obstructive Lung Disease 2014[Электронный ресурс]. Режим доступа: http://www.goldcopd.org/117.Thogersen, AM.
High plasminogen activator inhibitor and tissueplasminogen activator levels in plasma precede a first acute myocardial infarction inboth men and women - Evidence for the fibrinolytic system as an independentprimary risk factor. / AM Thogersen, JH Jansson, K Boman [et al.]// Circulation.1998.- Vol. 98(21).- P. 2241–7.95118.To, M. Sputum plasminogen activator inhibitor-1 elevation byoxidative stress-dependent nuclear factor-κB activation in COPD. / M To, D Takagi,K Akashi [et al.]// Chest.- 2013.- Vol. 144(2).- P. 515-21.119.Van der Hagen, PB. Subclinical atherosclerosis and the risk of futurevenous thrombosis in the Cardiovascular Health Study. / PB Van der Hagen, ARFolsom, NS Jenny [et al.]// J Thromb Haemost.- 2006.- Vol. 4(9).- P.
1903-8.120.Van Goor, M.L. The plasminogen activator inhibitor (PAI-1) 4G/5Gpromoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study./ M.L. Van Goor, E.G.García, F.Leebeek [et al.]// Thromb. Haemost.- 2005.Vol.93– P.92-96.121.Vaughan, D.E. PAI-1 antagonists: predictable indications andunconventional applications. / D.E Vaughan., B.M.De Taeye, M.Eren// Curr. DrugTargets.- 2007.- Vol. 8.- P. 962–970.122.Virchow, R. Phlogose und Thrombose im Gefäßsystem.
GesammelteAbhandlungenzurWissenschaftlichenMedizin.Frankfurt,Germany:Staatsdruckerei.- 1856.123.Vossen, CY. Risk of arterial thrombosis in carriers of familialthrombophilia. / CY Vossen, FR Rosendaal [et al.]// J Thromb Haemost.- 2006.Vol. 4. - P. 916–8.124.Whitemann,T.Hypercoagulablestates./T.Whitemann,H.I.Hassouna // Hemat. Oncol. Clin. N. Am.- 2000-Vol.14.- P. 1431–1448.125.Wiklund, P. Plasminogen activator inhibitor-1 4G/5G polymorphismand risk of stroke: replicated findings in two nested case-control studies based onindependent cohorts.
/ P.Wiklund, L.Nilsson, S.Nilsson [et al.]// Stroke.- 2005.Vol. 36.- P. 1661-1665.96126.Woodvard, M. A comparison of the association betveen sevenhemostatic or inflammatory variables and coronary heart disease. / M.Woodvard,A.Rumley, P.Welsh [et al.] // J Thromb Haemost.- 2007.- Vol. 5.- P. 1795-1800.127.Wu, JF. Platelet factor 4 and β-thromboglobulin in blood plasma ofpatients with acute exacerbation of chronic obstructive pulmonary disease / JF Wu,YH Yang, BS Pang// Zhonghua Yi Xue Za Zhi.- 2013.- Vol.
93(18).- P. 1378-82.128.Xu, X. Plasminogen activator inhibitor-1 promotes inflammatoryprocess induced by cigarette smoke extraction or lipopolysaccharides in alveolarepithelial cells. / X Xu, H Wang, Z Wang, W Xiao// Exp Lung Res. -2009.- Vol.35(9).- P.-795-805.129.Yamada, N. The 4G/5G polymorphism of the plasminogen activatorinhibitor-1 gene is associated with severe preeclampsia.
/ N.Yamada, T.Arinami,K.Yamakawa-Kobayashi// J. Hum. Genet.- 2000.- Vol. 45. -P.138-149797.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
